Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

An updated review of adipose derived-mesenchymal stem cells and their applications in musculoskeletal disorders.

Rivera-Izquierdo M., Cabeza L., Láinez-Ramos-Bossini A., Quesada R., Perazzoli G., Alvarez P.

Clinical Trial on Tendon Injury, Chronic Inflammation, Autoimmune Research, published in Expert Opin Biol Ther (2019) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Expert Opin Biol Ther (2019)
Country
England
Reported sample size
—
Source database
PubMed
PMID
30653367
DOI
10.1080/14712598.2019.1563069
Citations
30

Abstract (original English)

Introduction Adipose-derived mesenchymal stem cells (ASCs) represent a new therapeutic strategy in biomedicine with many potential applications, especially in musculoskeletal disorders. Preclinical and clinical studies based on the administration of ASCs support their efficacy in bone regeneration, joint repair, tendon injury and skeletal muscle alterations. Many of these novel treatments may improve patients' quality of life and prognosis. However, several concerns about the use of stem cells remain unsolved, particularly regarding their safety and side effects. The present work aims to review the nature, clinical trials and patents involving the use of ASCs in musculoskeletal disorders. Areas covered In this article, we describe ASCs' isolation, culture and differentiation in vivo and in vitro, advances on ASCs' applications in bone, cartilage, muscle and tendon repair, and patents involving the use of ASCs. Expert opinion The use of ASCs in musculoskeletal disorders presents significant therapeutic advantages, including limited autoimmune response, potential cell expansion ex vivo, high plasticity to differentiate into several mesodermal cell lineages, and additional effects of therapeutic interest such as secretion of neurotrophic factors and anti-inflammatory properties. For these reasons, ASCs are promising therapeutic agents for clinical applications in musculoskeletal d

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Adipose TissueAnimalsHumansMesenchymal Stem Cell TransplantationMesenchymal Stem CellsMusculoskeletal DiseasesQuality of LifeRegenerative MedicineTissue Engineering

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research